21 May 2009
Parathyroid hormone in living kidney donors after nephrectomy
M Bieniasz, A Kwiatkowski, P Domagała, J Gozdowska, R Kieszek, A Darocha, J Trzebicki, M Durlik, L Pączek, A ChmuraAnn Transplant 2009; 14(1): 57-57 :: ID: 880408
Abstract
Background: Living kidney donors loose half of their renal mass in a single
surgical event. After this loss, a series of compensations take place. Thus,
living kidney donors offer a unique opportunity to study the metabolic and
functional consequences resulting from loss of renal mass. The aim of this
study was to assess parathyroid hormone (PTH) in living kidney donors after unilateral nephrectomy.
Material/Methods: Between 1995 and 2005, 66 living donor open nephrectomies were performed. Physical examination, blood and urine tests and ultrasonography were performed prior to nephrectomy and at every 12 months post operation. We assessed basal PTH level. Donor mean age was 40.9 years (range 29-60). The donors were predominantly female (52.5%). 27 donors did not report for follow-up visits. Observation period ranged from 36 to 156 months post nephrectomy.
Results: Mean creatinine concentration increased from 0.89 mg/dl presurgery to 1.12 mg/dl at 36 months and to 1.1 mg/dl at 84 months post donation. Mean creatinine clearance according to Cockroft-Gault formula decreased from 94.27 ml/min before donation to 80.2 ml/min at 36 months and to 72.2 ml/min at 84 months after donating the kidney. One patient (2.6%) had a PTH level elevated to 94 pg/ml at 78 months post operation. His creatinine clearance according to Cockroft-Gault formula was 102 ml/min. We also observed a lowered PTH level in one patient at 52 months after nephrectomy.
Conclusions: Living kidney donation does not result in serious changes in
PTH levels in our investigated group. Further study with a longer observation period may be needed to evaluate parathyroid hormone imbalance in the long-term.
Keywords: Kidney Transplantation, Living Donors
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






